Nysa Membrane Technologies Inc. Raises Series B Venture Financing

    Innovative membrane technology company secures a second round Venture

    BURLINGTON, ON, Oct. 5 /CNW/ - Nysa Membrane Technologies Inc. announced
the closing of its second round of equity investment. Nysa's proprietary
membranes represent a truly disruptive technology, with dramatic cost and
performance advantages over conventional membrane and resin-based separation
    The investment was co-led by Jove Investment Management and BDC Venture
    Nysa will use the funds to further develop and commercialize its patent
pending, revolutionary, membrane-based platform technology and to build a
state of the art manufacturing facility. The company's novel, high value
products for specific applications, including large-scale bioprocessing,
small-scale bioanalytics, potable water, and food and beverage processing will
dramatically improve the safety and economics of biotechnology separations
required to purify proteins and other life sciences compounds. The disposable
nature of Nysa's separation products will enhance regulatory compliance and
obviate the need for costly and time-consuming cleaning and storage
    "Nysa's membranes represent a step-change improvement over conventional
technologies. They combine the advantages of conventional membranes and
chromatographic resins and can be cost-effectively deployed as pre-sterilized,
single-use disposables," said Andrew Fraser, Director, BDC Venture Capital.
"We are pleased to support Nysa in the commercialization of this disruptive
    "We are delighted to be an investor in this exciting business venture,"
said Michael Cross, Senior Vice President Venture Investments, Jove Investment
Management. "Nysa is a great example of how to spin technology out of a
university and commercialize it."

    About Nysa Membrane Technologies

    Nysa Membrane Technologies has developed a novel, patent-pending
membrane-based platform technology with broad worldwide applications in
protein purification and other biological & industrial separations. Nysa's
proprietary membranes represent a truly disruptive technology, with dramatic
cost and performance advantages over conventional membrane and resin-based
separation technologies. For more information see: www.nysamembranes.com.

    About Jove Capital (www.joviancapital.com)

    Jovian is a publicly-traded company listed on the TSX (JOV). Jovian is a
management and holding company with interests in a variety of financial
service firms specializing in wealth and asset management. The Jovian group of
companies operates as a national financial services organization with
approximately $15 billion of client assets ($5.5 billion assets under
management and $9.5 billion assets under administration).

    About BDC Venture Capital (www.bdc.ca)

    BDC Venture Capital is a major venture capital investor in Canada, active
at every stage of a company's development cycle, from seed through expansion.
Its focus is on technology-based businesses with high growth potential that
are positioned to become dominant players in their markets. Established in
1975, BDC Venture Capital has invested in over 400 firms to date. It currently
manages some $550 million in venture capital investments in the life sciences,
telecommunications, information technology, and advanced technology sectors,
as well as investments in funds. For more information, visit www.bdc.ca

For further information:

For further information: Dr. Lisa Crossley, President & CEO, Nysa
Membrane Technologies Inc., (905) 319-2682 x27, crossley@nysamembranes.com

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890